Altered Hypothalamic Protein Expression in a Rat Model of Huntington's Disease

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Cong, Wei na ^a   Cai, Huan ^a   Wang, Rui ^a   Daimon, Caitlin M ^a   Maudsley, Stuart ^a   Raber, Kerstin ^b   Canneva, Fabio ^b   von Hörsten, Stephan ^b   Martin, Bronwen ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACYLGLYCEROPHOSPHATE ACYLTRANSFERASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE PEROXIDASE; GLYCOGEN SYNTHASE; HEAT SHOCK PROTEIN 70; HIGH DENSITY LIPOPROTEIN; HORMONE; INSULIN; LEPTIN; LIPID; PROTEOME; TRIACYLGLYCEROL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DYSFUNCTION; BRAIN FUNCTION; BRAIN METABOLISM; COGNITIVE DEFECT; CONTROLLED STUDY; EARLY INTERVENTION; HUNTINGTON CHOREA; HYPOTHALAMUS; MALE; MOTOR DYSFUNCTION; NONHUMAN; PROTEIN EXPRESSION; RAT; SYMPTOMATOLOGY; TRANSGENIC RAT; TRINUCLEOTIDE REPEAT;

1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE PEROXIDASE; GLYCOGEN SYNTHASE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HUNTINGTON DISEASE; HYPOTHALAMUS; INSULIN; LEPTIN; LIPOPROTEINS, HDL; MALE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RATS; RATS, TRANSGENIC; TRIGLYCERIDES;

EID: 84867665193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047240     Document Type: Article

References (82)

1. Landles C, Bates GP, (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 5: 958-963.
2. Li SH, Li XJ, (2004) Huntington and its Role in Neuronal Degeneration. Neuroscientist 10: 467-475.
3. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
4. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, (2004) on behalf of an International Huntington's Disease Collaborative G (2004) A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics 65: 267-277.
5. Dewhurst K, Oliver J, (1970) Huntington's disease of young people. Eur Neurol 3: 278-289.
6. Brandt J, Folstein SE, Folstein MF, (1988) Differential cognitive impairment in Alzheimer's disease and Huntington's disease. Ann Neurol 23: 555-561.
7. Bamford KA, Caine ED, Kido DK, Cox C, Shoulson I, (1995) A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 45: 1867-1873.
8. Shiwach R, (1994) Psychopathology in Huntington's disease patients. Acta Psychiatr Scand 90: 241-246.
9. Sanberg PR, Fibiger HC, Mark RF, (1981) Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med J Aust 1: 407-409.
10. Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, et al. (2002) Weight loss in early stage of Huntington's disease. Neurology 59: 1325-1330.
11. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J, (2004) Rate and correlates of weight change in Huntington's disease. Journal of Neurology, Neurosurgery & Psychiatry 75: 209-212.
12. Ahmad Aziz N, Pijl H, Frölich M, Maurits van der Graaf AW, Roelfsema F, et al. (2009) Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients. Clinical Endocrinology 73: 206-211.
13. Podolsky S, Leopold NA, (1977) Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23: 55-63.
14. Kremer HP, Roos RA, Frolich M, Radder JK, Nieuwenhuijzen Kruseman AC, et al. (1989) Endocrine functions in Huntington's disease. A two-and-a-half years follow-up study. J Neurol Sci 90: 335-344.
15. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, et al. (2009) Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease. Diabetes 58: 318-328.
16. Trejo A, Tarrats RM, Alonso ME, Boll M-C, Ochoa A, et al. (2004) Assessment of the nutrition status of patients with Huntington's disease. Nutrition 20: 192-196.
17. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, et al. (2005) Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease. J Neurosci 25: 157-163.
18. Hult S, Soylu R, Björklund T, Belgardt BF, Mauer J, et al. (2011) Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metabolism 13(4): 428-39.
19. Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, et al. (2004) Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63: 66-72.
20. Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, et al. (2005) Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. Journal of Neurology, Neurosurgery & Psychiatry 76: 650-655.
21. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, et al. (2006) Brain structure in preclinical Huntington's Disease. Biological Psychiatry 59: 57-63.
22. Wolf RC, Vasic N, Schönfeldt-Lecuona C, Landwehrmeyer GB, Ecker D, (2007) Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 130: 2845-2857.
23. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, et al. (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65: 745-747.
24. Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, et al. (2010) Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease 40: 531-543.
25. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA, et al. (2009) Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiology of Disease 33: 20-27.
26. Björkqvist M, Leavitt BR, Nielsen JE, Landwehrmeyer B, Ecker D, et al. (2007) Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Movement Disorders 22: 1952-1954.
27. Gabery S, Murphy K, Schultz K, Loy C, McCusker E, et al. (2010) Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica 120: 777-788.
28. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
29. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, et al. (2006) Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences 103: 9345-9350.
30. von Hörsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, et al. (2003) Transgenic rat model of Huntington's disease. Human Molecular Genetics 12: 617-624.
31. Nguyen HP, Kobbe P, Rahne H, Wörpel T, Jäger B, et al. (2006) Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Human Molecular Genetics 15: 3177-3194.
32. Martin B, Golden E, Keselman A, Stone M, Mattson MP, et al. (2008) Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol Histopathol 23: 237-250.
33. van der Burg JMM, Björkqvist M, Brundin P, (2009) Beyond the brain: widespread pathology in Huntington's disease. The Lancet Neurology 8: 765-774.
34. Cai H, Cong WN, Ji S, Rothman S, Maudsley S, et al. (2012) Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res 9: 5-17.
35. Hult S, Schultz K, Soylu R, Petersén A, (2010) Hypothalamic and neuroendocrine changes in Huntington's disease. Curr Drug Targets 11: 1237-1249.
36. Lalic NM, Maric J, Svetel M, Jotic A, Stefanova E, et al. (2008) Glucose Homeostasis in Huntington disease. Arch neurol 65: 476-480.
37. Farrer LA, (1985) Diabetes Mellitus in Huntington's disease. Clin Genet 27: 62-67.
38. Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, et al. (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur J Endocrinol 151: 451-5.
39. Scherbaum WA, (1998) The role of amylin in the physiology of glycemic control. Exp Clin Endocrinol Diabetes 106: 97-102.
40. Boey D, Sainsbury A, Herzog H, (2007) The role of peptide YY in regulating glucose homeostasis. Peptides 28: 390-395.
41. Tomita M, (2011) Islet amu;oid polypeptide in pancreatic islets from type 1 diabetic subjects. Islets 3: 166-174.
42. Hashimoto K-I, Ito Y, Tanahashi H, Hayashi M, Yamakita N, et al. (2012) Hyperglycemic Chorea-Ballism or Acute Exacerbation of Huntington's Chorea? Huntington's DiseaseUnmasked by Diabetic Ketoacidosis in Type 1 Diabetes Mellitus. Clin Endocrinol Metab [Epub ahead of print].
43. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, et al. (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48: 649-651.
44. Martin B, Brenneman R, Becker KG, Gucek M, Cole RN, et al. (2008) iTRAQ Analysis of Complex Proteome Alterations in 3×TgAD Alzheimer's Mice: Understanding the Interface between Physiology and Disease. PLoS ONE 3: e2750.
45. Ding WG, Gromada J, (1997) Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 46: 615-621.
46. Schwartz TW, Holst JJ, Fahrenkrug J, Jensen SL, Nielsen OV, et al. (1978) Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 61: 781-789.
47. Baggio LL, Drucker DJ, (2007) Biology of Incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
48. Field BCT, Chaudhri OB, Bloom SR, (2010) Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 6: 444-453.
49. Faivre E, Hamilton A, Holscher C, (2012) Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. European Journal of Pharmacology 674: 294-306.
50. Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K, (2009) Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet 18: 1006-1016.
51. Leoni V, Mariotti C, Nanetti L, Salvatore E, Squitieri F, et al. (2011) Whole body cholesterol metabolism is impaired in Huntington's disease. Neurosci Lett 494: 245-9.
52. Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, et al. (2010) Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 30: 10844-10850.
53. Salvatore E, Rinaldi C, Tucci T, Di Maio L, Di Somma C, et al. (2011) Growth hormone response to arginine test differentiates between two subgroups of Huntington's disease patients. J Neurol Neurosurg Psychiatry 82: 543-7.
54. Whittier JR, (1976) Letter: Asphyxiation, bulimia, and insulin levels in Huntington disease (chorea). JAMA 235: 1423-1424.
55. Peterson A, Hult S, Kirik D, (2009) Huntington's Disease:New Perspectives Based on Neuroendocrine Changes in Rodent Models. Neurodegenerative Diseases 6: 154-164.
56. Chadwick W, Martin B, Chapter MC, Park SS, Wang L, et al. (2012) GIT2 acts as a potential keystone protein in functional hypothalamic networks associated with age-related phenotypic changes in rats. PLoS One 7 (5):: e36975.
57. Middeldorp J, Hol EM, (2011) GFAP in health and disease. Prog Neurobiol 93: 421-43.
58. De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, et al. (2002) Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 70: 726-36.
59. Zhao WQ, Lu B, (2007) Expression of annexin A2 in GABAergic interneurons in the normal rat brain. J Neurochem 100: 1211-23.
60. Lalli G, (2009) RalA and the exocyst complex influence neuronal polarity through PAR-3 and aPKC. J Cell Sci 122: 1499-506.
61. Lotz GP, Legleiter J, Aron R, Mitchell EJ, Huang SY, et al. (2010) Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem 285: 38183-93.
62. Braunstein KE, Eschbach J, Ròna-Vörös K, Soylu R, Mikrouli E, et al. (2010) A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Hum Mol Genet 19: 4385-98.
63. Bellinger FP, Bellinger MT, Seale LA, Takemoto AS, Raman AV, et al. (2011) Glutathione peroxidase 4 is associated with neuromelanin in Substantia Nigra and dystrophic axons in putamen of Parkinson's brain. Mol Neurodegener 6: 8.
64. Raza H, (2011) Dual localization of glutathione S-transferase in the cytosol and mitochondria: implications in oxidative stress, toxicity and disease. FEBS J 278: 4243-51.
65. Stranahan AM, Lee K, Becker KG, Zhang Y, Maudsley S, et al. (2010) Hippocampal gene expression patterns underlying the enhancement of memory by running in aged mice. Neurobiology of Aging 31: 1937-1949.
66. Irimia JM, Meyer CM, Peper CL, Zhai L, Bock CB, et al. (2010) Impaired Glucose Tolerance and Predisposition to the Fasted State in Liver Glycogen Synthase Knock-out Mice. Journal of Biological Chemistry 285: 12851-12861.
67. Holness MJ, Bulmer K, Smith ND, Sugden MC, (2003) Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone. Biochem J 369: 687-695.
68. Mayers RM, Leighton B, Kilgour E, (2005) PDH kinase inhibitors: a novel therapy for Type II diabetes? Biochem Soc Trans 33: 367-370.
69. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, et al. (2009) Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Experimental Cell Research 315: 2765-2774.
70. Takeuchi K, Reue K, (2009) Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. American Journal of Physiology- Endocrinology And Metabolism 296: E1195-E1209.
71. Pohl J, Ring A, Herrmann T, Stremmel W, (2004) New concepts of cellular fatty acid uptake: role of fatty acid transport proteins and of caveolae. Proceedings of the Nutrition Society 63: 259-262.
72. López M, Vidal-Puig A, (2008) Brain lipogenesis and regulation of energy metabolism. Curr Opin Clin Nutr Metab Care 11: 483-490.
73. Martin B, Shin YK, White CM, Ji S, Kim W, et al. (2010) Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression. Diabetes 59: 1143-52.
74. Martin B, Pearson M, Kebejian L, Golden E, Keselman A, et al. (2007) Sex-dependent metabolic, neuroendocrine, and cognitive responses to dietary energy restriction and excess. Endocrinology 148: 4318-33.
75. Rothman SM, Herdener N, Camandola S, Texel SJ, Mughal MR, et al. (2012) 3×TgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress. Neurobiol Aging 33: 830.e1-12.
76. Griffiths SD, Burthem J, Unwin RD, Holyoake TL, Melo JV, et al. (2007) The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol Biotechnol 36: 81-89.
77. Martin B, Brenneman R, Golden E, Walent T, Becker KG, (2009) et al. Growth factor signals in neural cells: coherent patterns of interaction control multiple levels of molecular and phenotypic responses. J Biol Chem 284: 2493-511.
78. Chadwick W, Boyle JP, Zhou Y, Wang L, Park SS, et al. (2011) Multiple oxygen tension environments reveal diverse patterns of transcriptional regulation in primary astrocytes. PLoS One 6: e21638.
79. Martin B, Pearson M, Brenneman R, Golden E, Wood W, et al. (2009) Gonadal transcriptome alterations in response to dietary energy intake: sensing the reproductive environment. PLoS One 4: e4146.
80. Chadwick W, Zhou Y, Park SS, Wang L, Mitchell N, et al. (2010) Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One 5: e14352.
81. Chadwick W, Brenneman R, Martin B, Maudsley S, (2010) Complex and multidimensional lipid raft alterations in a murine model of Alzheimer's disease. Int J Alzheimers Dis 604792.
82. Chadwick W, Park SS, Zhou Y, Wang L, Brenneman R, et al. (2011) Repetitive peroxide exposure reveals pleiotropic mitogen-activated protein kinase signaling mechanisms. J Signal Transduct pii pp. 636951.